1
|
Çerçi B, Gök A, Akyol A. Brain-derived neurotrophic factor: Its role in energy balance and cancer cachexia. Cytokine Growth Factor Rev 2023; 71-72:105-116. [PMID: 37500391 DOI: 10.1016/j.cytogfr.2023.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 07/14/2023] [Accepted: 07/16/2023] [Indexed: 07/29/2023]
Abstract
Brain-derived neurotrophic factor (BDNF) plays an important role in the development of the central and peripheral nervous system during embryogenesis. In the mature central nervous system, BDNF is required for the maintenance and enhancement of synaptic transmissions and the survival of neurons. Particularly, it is involved in the modulation of neurocircuits that control energy balance through food intake, energy expenditure, and locomotion. Regulation of BDNF in the central nervous system is complex and environmental factors affect its expression in murine models which may reflect to phenotype dramatically. Furthermore, BDNF and its high-affinity receptor tropomyosin receptor kinase B (TrkB), as well as pan-neurotrophin receptor (p75NTR) is expressed in peripheral tissues in adulthood and their signaling is associated with regulation of energy balance. BDNF/TrkB signaling is exploited by cancer cells as well and BDNF expression is increased in tumors. Intriguingly, previously demonstrated roles of BDNF in regulation of food intake, adipose tissue and muscle overlap with derangements observed in cancer cachexia. However, data about the involvement of BDNF in cachectic cancer patients and murine models are scarce and inconclusive. In the future, knock-in and/or knock-out experiments with murine cancer models could be helpful to explore potential new roles for BDNF in the development of cancer cachexia.
Collapse
Affiliation(s)
- Barış Çerçi
- Medical School, Hacettepe University, Ankara, Turkey.
| | - Ayşenur Gök
- Department of Stem Cell Sciences, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkey; Hacettepe University Transgenic Animal Technologies Research and Application Center, Sıhhiye, Ankara 06100, Turkey
| | - Aytekin Akyol
- Departmant of Pathology, Medical School, Hacettepe University, Ankara, Turkey; Hacettepe University Transgenic Animal Technologies Research and Application Center, Sıhhiye, Ankara 06100, Turkey
| |
Collapse
|
2
|
Clarke E, Stocki P, Sinclair EH, Gauhar A, Fletcher EJR, Krawczun-Rygmaczewska A, Duty S, Walsh FS, Doherty P, Rutkowski JL. A Single Domain Shark Antibody Targeting the Transferrin Receptor 1 Delivers a TrkB Agonist Antibody to the Brain and Provides Full Neuroprotection in a Mouse Model of Parkinson’s Disease. Pharmaceutics 2022; 14:pharmaceutics14071335. [PMID: 35890231 PMCID: PMC9318160 DOI: 10.3390/pharmaceutics14071335] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/20/2022] [Accepted: 06/22/2022] [Indexed: 02/04/2023] Open
Abstract
Single domain shark antibodies that bind to the transferrin receptor 1 (TfR1) on brain endothelial cells have been used to shuttle antibodies and other cargos across the blood brain barrier (BBB) to the brain. For these studies the TXB4 brain shuttle was fused to a TrkB neurotrophin receptor agonist antibody. The TXB4-TrkB fusion retained potent agonist activity at its cognate receptor and after systemic administration showed a 12-fold increase in brain levels over the unmodified antibody. Only the TXB4-TrkB antibody fusion was detected within the brain and localized to TrkB positive cells in the cortex and tyrosine hydroxylase (TH) positive dopaminergic neurons in the substantia nigra pars compacta (SNc), where it was associated with activated ERK1/2 signaling. When tested in the 6-hydroxydopamine (6-OHDA) mouse model of Parkinson’s disease (PD), TXB4-TrkB, but not the unmodified antibody, completely prevented the 6-OHDA induced death of TH positive neurons in the SNc. In conclusion, the fusion of the TXB4 brain shuttle allows a TrkB agonist antibody to reach neuroprotective concentrations in the brain parenchyma following systemic administration.
Collapse
Affiliation(s)
- Emily Clarke
- King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Disease, Guy’s Campus, London SE1 1UL, UK; (E.C.); (E.J.R.F.); (A.K.-R.); (S.D.); (P.D.)
| | - Pawel Stocki
- Ossianix, Inc., Gunnels Wood Rd., Stevenage SG1 2FX, UK; (P.S.); (E.H.S.); (A.G.); (F.S.W.)
| | - Elizabeth H. Sinclair
- Ossianix, Inc., Gunnels Wood Rd., Stevenage SG1 2FX, UK; (P.S.); (E.H.S.); (A.G.); (F.S.W.)
| | - Aziz Gauhar
- Ossianix, Inc., Gunnels Wood Rd., Stevenage SG1 2FX, UK; (P.S.); (E.H.S.); (A.G.); (F.S.W.)
| | - Edward J. R. Fletcher
- King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Disease, Guy’s Campus, London SE1 1UL, UK; (E.C.); (E.J.R.F.); (A.K.-R.); (S.D.); (P.D.)
| | - Alicja Krawczun-Rygmaczewska
- King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Disease, Guy’s Campus, London SE1 1UL, UK; (E.C.); (E.J.R.F.); (A.K.-R.); (S.D.); (P.D.)
| | - Susan Duty
- King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Disease, Guy’s Campus, London SE1 1UL, UK; (E.C.); (E.J.R.F.); (A.K.-R.); (S.D.); (P.D.)
| | - Frank S. Walsh
- Ossianix, Inc., Gunnels Wood Rd., Stevenage SG1 2FX, UK; (P.S.); (E.H.S.); (A.G.); (F.S.W.)
| | - Patrick Doherty
- King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Disease, Guy’s Campus, London SE1 1UL, UK; (E.C.); (E.J.R.F.); (A.K.-R.); (S.D.); (P.D.)
| | - Julia Lynn Rutkowski
- Ossianix, Inc., Gunnels Wood Rd., Stevenage SG1 2FX, UK; (P.S.); (E.H.S.); (A.G.); (F.S.W.)
- Correspondence: ; Tel.: +1-(610)-291-1724
| |
Collapse
|
3
|
Tessarollo L, Yanpallewar S. TrkB Truncated Isoform Receptors as Transducers and Determinants of BDNF Functions. Front Neurosci 2022; 16:847572. [PMID: 35321093 PMCID: PMC8934854 DOI: 10.3389/fnins.2022.847572] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2022] [Accepted: 02/10/2022] [Indexed: 11/24/2022] Open
Abstract
Brain-derived neurotrophic factor (BDNF) belongs to the neurotrophin family of secreted growth factors and binds with high affinity to the TrkB tyrosine kinase receptors. BDNF is a critical player in the development of the central (CNS) and peripheral (PNS) nervous system of vertebrates and its strong pro-survival function on neurons has attracted great interest as a potential therapeutic target for the management of neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS), Huntington, Parkinson’s and Alzheimer’s disease. The TrkB gene, in addition to the full-length receptor, encodes a number of isoforms, including some lacking the catalytic tyrosine kinase domain. Importantly, one of these truncated isoforms, namely TrkB.T1, is the most widely expressed TrkB receptor in the adult suggesting an important role in the regulation of BDNF signaling. Although some progress has been made, the mechanism of TrkB.T1 function is still largely unknown. Here we critically review the current knowledge on TrkB.T1 distribution and functions that may be helpful to our understanding of how it regulates and participates in BDNF signaling in normal physiological and pathological conditions.
Collapse
|
4
|
Qin X, Zhao Y, Zhang T, Yin C, Qiao J, Guo W, Lu B. TrkB agonist antibody ameliorates fertility deficits in aged and cyclophosphamide-induced premature ovarian failure model mice. Nat Commun 2022; 13:914. [PMID: 35177657 PMCID: PMC8854395 DOI: 10.1038/s41467-022-28611-2] [Citation(s) in RCA: 40] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 01/12/2022] [Indexed: 12/18/2022] Open
Abstract
Premature ovarian failure (POF) is a leading cause of women's infertility without effective treatment. Here we show that intravenous injection of Ab4B19, an agonistic antibody for the BDNF receptor TrkB, penetrates into ovarian follicles, activates TrkB signaling, and promotes ovary development. In both natural aging and cyclophosphamide-induced POF models, treatment with Ab4B19 completely reverses the reduction of pre-antral and antral follicles, and normalizes gonadal hormone. Ab4B19 also attenuates gonadotoxicity and inhibits apoptosis in cyclophosphamide-induced POF ovaries. Further, treatment with Ab4B19, but not BDNF, restores the number and quality of oocytes and enhances fertility. In human, BDNF levels are high in granulosa cells and TrkB levels increase in oocytes as they mature. Moreover, BDNF expression is down-regulated in follicles of aged women, and Ab4B19 activates TrkB signaling in human ovary tissue ex vivo. These results identify TrkB as a potential target for POF with differentiated mechanisms, and confirms superiority of TrkB activating antibody over BDNF as therapeutic agents.
Collapse
Affiliation(s)
- Xunsi Qin
- School of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Joint Graduate Program of Peking-Tsinghua-NIBS, Tsinghua University, Beijing, 100084, China
- Beijing Tiantan Hospital, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100070, China
| | - Yue Zhao
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China
- Research Units of Comprehensive Diagnosis and Treatment of Oocyte Maturation Arrest, Chinese Academy of Medical Sciences, Beijing, 100191, China
| | - Tianyi Zhang
- School of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Joint Graduate Program of Peking-Tsinghua-NIBS, Tsinghua University, Beijing, 100084, China
- Beijing Tiantan Hospital, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100070, China
| | - Chenghong Yin
- Department of Internal Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China
| | - Jie Qiao
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China
- Research Units of Comprehensive Diagnosis and Treatment of Oocyte Maturation Arrest, Chinese Academy of Medical Sciences, Beijing, 100191, China
| | - Wei Guo
- School of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Joint Graduate Program of Peking-Tsinghua-NIBS, Tsinghua University, Beijing, 100084, China.
- Beijing Tiantan Hospital, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100070, China.
| | - Bai Lu
- School of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Joint Graduate Program of Peking-Tsinghua-NIBS, Tsinghua University, Beijing, 100084, China.
- Beijing Tiantan Hospital, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100070, China.
| |
Collapse
|
5
|
Paulo SL, Miranda-Lourenço C, Belo RF, Rodrigues RS, Fonseca-Gomes J, Tanqueiro SR, Geraldes V, Rocha I, Sebastião AM, Xapelli S, Diógenes MJ. High Caloric Diet Induces Memory Impairment and Disrupts Synaptic Plasticity in Aged Rats. Curr Issues Mol Biol 2021; 43:2305-2319. [PMID: 34940136 PMCID: PMC8929079 DOI: 10.3390/cimb43030162] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 12/08/2021] [Accepted: 12/13/2021] [Indexed: 12/26/2022] Open
Abstract
The increasing consumption of sugar and fat seen over the last decades and the consequent overweight and obesity, were recently linked with a deleterious effect on cognition and synaptic function. A major question, which remains to be clarified, is whether obesity in the elderly is an additional risk factor for cognitive impairment. We aimed at unravelling the impact of a chronic high caloric diet (HCD) on memory performance and synaptic plasticity in aged rats. Male rats were kept on an HCD or a standard diet (control) from 1 to 24 months of age. The results showed that under an HCD, aged rats were obese and displayed significant long-term recognition memory impairment when compared to age-matched controls. Ex vivo synaptic plasticity recorded from hippocampal slices from HCD-fed aged rats revealed a reduction in the magnitude of long-term potentiation, accompanied by a decrease in the levels of the brain-derived neurotrophic factor receptors TrkB full-length (TrkB-FL). No alterations in neurogenesis were observed, as quantified by the density of immature doublecortin-positive neurons in the hippocampal dentate gyrus. This study highlights that obesity induced by a chronic HCD exacerbates age-associated cognitive decline, likely due to impaired synaptic plasticity, which might be associated with deficits in TrkB-FL signaling.
Collapse
Affiliation(s)
- Sara L. Paulo
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (S.L.P.); (C.M.-L.); (R.F.B.); (R.S.R.); (J.F.-G.); (S.R.T.); (A.M.S.); (S.X.)
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Catarina Miranda-Lourenço
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (S.L.P.); (C.M.-L.); (R.F.B.); (R.S.R.); (J.F.-G.); (S.R.T.); (A.M.S.); (S.X.)
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Rita F. Belo
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (S.L.P.); (C.M.-L.); (R.F.B.); (R.S.R.); (J.F.-G.); (S.R.T.); (A.M.S.); (S.X.)
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Rui S. Rodrigues
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (S.L.P.); (C.M.-L.); (R.F.B.); (R.S.R.); (J.F.-G.); (S.R.T.); (A.M.S.); (S.X.)
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - João Fonseca-Gomes
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (S.L.P.); (C.M.-L.); (R.F.B.); (R.S.R.); (J.F.-G.); (S.R.T.); (A.M.S.); (S.X.)
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Sara R. Tanqueiro
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (S.L.P.); (C.M.-L.); (R.F.B.); (R.S.R.); (J.F.-G.); (S.R.T.); (A.M.S.); (S.X.)
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Vera Geraldes
- Instituto de Fisiologia, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (V.G.); (I.R.)
- Centro Cardiovascular da Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Isabel Rocha
- Instituto de Fisiologia, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (V.G.); (I.R.)
- Centro Cardiovascular da Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Ana M. Sebastião
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (S.L.P.); (C.M.-L.); (R.F.B.); (R.S.R.); (J.F.-G.); (S.R.T.); (A.M.S.); (S.X.)
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Sara Xapelli
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (S.L.P.); (C.M.-L.); (R.F.B.); (R.S.R.); (J.F.-G.); (S.R.T.); (A.M.S.); (S.X.)
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Maria J. Diógenes
- Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal; (S.L.P.); (C.M.-L.); (R.F.B.); (R.S.R.); (J.F.-G.); (S.R.T.); (A.M.S.); (S.X.)
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
- Correspondence: ; Tel.: +351-217-985-183
| |
Collapse
|
6
|
Wie J, Liu Z, Song H, Tropea TF, Yang L, Wang H, Liang Y, Cang C, Aranda K, Lohmann J, Yang J, Lu B, Chen-Plotkin AS, Luk KC, Ren D. A growth-factor-activated lysosomal K + channel regulates Parkinson's pathology. Nature 2021; 591:431-437. [PMID: 33505021 DOI: 10.1038/s41586-021-03185-z] [Citation(s) in RCA: 53] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Accepted: 12/10/2020] [Indexed: 12/11/2022]
Abstract
Lysosomes have fundamental physiological roles and have previously been implicated in Parkinson's disease1-5. However, how extracellular growth factors communicate with intracellular organelles to control lysosomal function is not well understood. Here we report a lysosomal K+ channel complex that is activated by growth factors and gated by protein kinase B (AKT) that we term lysoKGF. LysoKGF consists of a pore-forming protein TMEM175 and AKT: TMEM175 is opened by conformational changes in, but not the catalytic activity of, AKT. The minor allele at rs34311866, a common variant in TMEM175, is associated with an increased risk of developing Parkinson's disease and reduces channel currents. Reduction in lysoKGF function predisposes neurons to stress-induced damage and accelerates the accumulation of pathological α-synuclein. By contrast, the minor allele at rs3488217-another common variant of TMEM175, which is associated with a decreased risk of developing Parkinson's disease-produces a gain-of-function in lysoKGF during cell starvation, and enables neuronal resistance to damage. Deficiency in TMEM175 leads to a loss of dopaminergic neurons and impairment in motor function in mice, and a TMEM175 loss-of-function variant is nominally associated with accelerated rates of cognitive and motor decline in humans with Parkinson's disease. Together, our studies uncover a pathway by which extracellular growth factors regulate intracellular organelle function, and establish a targetable mechanism by which common variants of TMEM175 confer risk for Parkinson's disease.
Collapse
Affiliation(s)
- Jinhong Wie
- Department of Biology, University of Pennsylvania, Philadelphia, PA, USA
| | - Zhenjiang Liu
- Department of Biology, University of Pennsylvania, Philadelphia, PA, USA
| | - Haikun Song
- State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, School of Life Sciences, Fudan University, Shanghai, China
| | - Thomas F Tropea
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Lu Yang
- School of Life Sciences, IDG/McGovern Institute for Brain Research, Peking University, Beijing, China
| | - Huanhuan Wang
- School of Life Sciences, IDG/McGovern Institute for Brain Research, Peking University, Beijing, China
| | - Yuling Liang
- Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Chunlei Cang
- Department of Biology, University of Pennsylvania, Philadelphia, PA, USA
| | - Kimberly Aranda
- Department of Biology, University of Pennsylvania, Philadelphia, PA, USA
| | - Joey Lohmann
- Department of Biology, University of Pennsylvania, Philadelphia, PA, USA
| | - Jing Yang
- School of Life Sciences, IDG/McGovern Institute for Brain Research, Peking University, Beijing, China
| | - Boxun Lu
- State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, School of Life Sciences, Fudan University, Shanghai, China
| | - Alice S Chen-Plotkin
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
| | - Kelvin C Luk
- Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
| | - Dejian Ren
- Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.
| |
Collapse
|
7
|
Wang S, Yao H, Xu Y, Hao R, Zhang W, Liu H, Huang Y, Guo W, Lu B. Therapeutic potential of a TrkB agonistic antibody for Alzheimer's disease. Am J Cancer Res 2020; 10:6854-6874. [PMID: 32550908 PMCID: PMC7295064 DOI: 10.7150/thno.44165] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Accepted: 05/11/2020] [Indexed: 12/26/2022] Open
Abstract
Repeated failures of “Aβ-lowering” therapies call for new targets and therapeutic approaches for Alzheimer's disease (AD). We propose to treat AD by halting neuronal death and repairing synapses using a BDNF-based therapy. To overcome the poor druggability of BDNF, we have developed an agonistic antibody AS86 to mimic the function of BDNF, and evaluate its therapeutic potential for AD. Method: Biochemical, electrophysiological and behavioral techniques were used to investigate the effects of AS86 in vitro and in vivo. Results: AS86 specifically activated the BDNF receptor TrkB and its downstream signaling, without affecting its other receptor p75NTR. It promoted neurite outgrowth, enhanced spine growth and prevented Aβ-induced cell death in cultured neurons, and facilitated Long-Term Potentiation (LTP) in hippocampal slices. A single-dose tail-vein injection of AS86 activated TrkB signaling in the brain, with a half-life of 6 days in the blood and brain. Bi-weekly peripheral administration of AS86 rescued the deficits in object-recognition memory in the APP/PS1 mouse model. AS86 also reversed spatial memory deficits in the 11-month, but not 14-month old AD mouse model. Conclusion: These results demonstrate the potential of AS86 in AD therapy, suggesting that neuronal and/or synaptic repair as an alternative therapeutic strategy for AD.
Collapse
|
8
|
Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities. Neural Plast 2020; 2020:1969482. [PMID: 32399020 PMCID: PMC7204205 DOI: 10.1155/2020/1969482] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 10/14/2019] [Accepted: 11/08/2019] [Indexed: 12/17/2022] Open
Abstract
With the rise in the aging global population, stroke comorbidities have become a serious health threat and a tremendous economic burden on human society. Current therapeutic strategies mainly focus on protecting neurons from cytotoxic damage at the acute phase upon stroke onset, which not only is a difficult way to ameliorate stroke symptoms but also presents a challenge for the patients to receive effective treatment in time. The brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in the adult brain, which possesses a remarkable capability to repair brain damage. Recent promising preclinical outcomes have made BDNF a popular late-stage target in the development of novel stroke treatments. In this review, we aim to summarize the latest progress in the understanding of the cellular/molecular mechanisms underlying stroke pathogenesis, current strategies and difficulties in drug development, the mechanism of BDNF action in poststroke neurorehabilitation and neuroplasticity, and recent updates in novel therapeutic methods.
Collapse
|
9
|
Markofski MM, Jennings K, Dolan C, Davies NA, LaVoy EC, Ryan EJ, Carrillo AE. Single-Arm 8-Week Ad Libitum Self-Prepared Paleo Diet Reduces Cardiometabolic Disease Risk Factors in Overweight Adults. Am J Lifestyle Med 2019; 15:690-700. [PMID: 34916890 DOI: 10.1177/1559827619866157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The paleo diet is popular among the general population due to promoted weight loss and disease prevention benefits. We examined the effectiveness of a self-administered paleo diet in improving cardiometabolic disease risk factors. Overweight, physically inactive but otherwise healthy adults (males = 4, females = 3, age 32.7 ± 4.9 years, body mass index [BMI] 29.4 ± 2.4 kg/m2) habitually eating a traditional Western diet (1853.4 ± 441.2 kcal; 34.0% carbohydrate; 41.4% fat; 19.2% protein) completed an ad libitum self-administered paleo diet for 8 weeks. Height, weight, blood pressure, and a fasting blood sample were collected pre- and post-paleo dietary intervention. Blood samples were analyzed for fasting cardiometabolic disease biomarkers-including brain-derived neurotropic factor (BDNF), fibroblast growth factor (FGF) 21, and leptin. After 8 weeks, body mass (-5.3 kg, P = .008), BMI (-1.7 kg/m2, P = .002), serum leptin (-56.2%, P = .012), serum FGF21 (-26.7%, P = .002), and serum BDNF (-25.8%, P = .045) significantly decreased. Systolic and diastolic blood pressure were unchanged following the paleo dietary intervention (P > .05). Average energy intake (-412.6 kcal, P = .016) significantly decreased with the paleo dietary intervention mostly due to a reduction in carbohydrate consumption (-69.2 g; P = .003). An 8-week self-administered paleo dietary intervention was effective in improving cardiometabolic disease risk factors in a healthy, physically inactive overweight adult population.
Collapse
Affiliation(s)
- Melissa M Markofski
- Laboratory of Integrative Physiology, Department of Health and Human Performance, University of Houston, Houston, Texas (MMM, CD, ECL).,Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas (KJ).,Department of Exercise Science, Chatham University, Pittsburgh, Pennsylvania (NAD, EJR, AEC).,FAME Laboratory, Department of Exercise Science, University of Thessaly, Karies, Trikala, Greece (AEC)
| | - Kristofer Jennings
- Laboratory of Integrative Physiology, Department of Health and Human Performance, University of Houston, Houston, Texas (MMM, CD, ECL).,Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas (KJ).,Department of Exercise Science, Chatham University, Pittsburgh, Pennsylvania (NAD, EJR, AEC).,FAME Laboratory, Department of Exercise Science, University of Thessaly, Karies, Trikala, Greece (AEC)
| | - Chad Dolan
- Laboratory of Integrative Physiology, Department of Health and Human Performance, University of Houston, Houston, Texas (MMM, CD, ECL).,Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas (KJ).,Department of Exercise Science, Chatham University, Pittsburgh, Pennsylvania (NAD, EJR, AEC).,FAME Laboratory, Department of Exercise Science, University of Thessaly, Karies, Trikala, Greece (AEC)
| | - Natalie A Davies
- Laboratory of Integrative Physiology, Department of Health and Human Performance, University of Houston, Houston, Texas (MMM, CD, ECL).,Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas (KJ).,Department of Exercise Science, Chatham University, Pittsburgh, Pennsylvania (NAD, EJR, AEC).,FAME Laboratory, Department of Exercise Science, University of Thessaly, Karies, Trikala, Greece (AEC)
| | - Emily C LaVoy
- Laboratory of Integrative Physiology, Department of Health and Human Performance, University of Houston, Houston, Texas (MMM, CD, ECL).,Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas (KJ).,Department of Exercise Science, Chatham University, Pittsburgh, Pennsylvania (NAD, EJR, AEC).,FAME Laboratory, Department of Exercise Science, University of Thessaly, Karies, Trikala, Greece (AEC)
| | - Edward J Ryan
- Laboratory of Integrative Physiology, Department of Health and Human Performance, University of Houston, Houston, Texas (MMM, CD, ECL).,Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas (KJ).,Department of Exercise Science, Chatham University, Pittsburgh, Pennsylvania (NAD, EJR, AEC).,FAME Laboratory, Department of Exercise Science, University of Thessaly, Karies, Trikala, Greece (AEC)
| | - Andres E Carrillo
- Laboratory of Integrative Physiology, Department of Health and Human Performance, University of Houston, Houston, Texas (MMM, CD, ECL).,Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas (KJ).,Department of Exercise Science, Chatham University, Pittsburgh, Pennsylvania (NAD, EJR, AEC).,FAME Laboratory, Department of Exercise Science, University of Thessaly, Karies, Trikala, Greece (AEC)
| |
Collapse
|
10
|
Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C. Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. JCO Precis Oncol 2018; 2:1-7. [PMID: 35135135 DOI: 10.1200/po.18.00039] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Affiliation(s)
- Michael J Pishvaian
- Michael J. Pishvaian and Stephen V. Liu, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Pratik S. Multani and Edna Chow-Maneval, Ignyta, San Diego, CA; and Christian Rolfo, Antwerp University Hospital and Center of Oncological Research, Antwerp University, Antwerp, Belgium
| | - Ignacio Garrido-Laguna
- Michael J. Pishvaian and Stephen V. Liu, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Pratik S. Multani and Edna Chow-Maneval, Ignyta, San Diego, CA; and Christian Rolfo, Antwerp University Hospital and Center of Oncological Research, Antwerp University, Antwerp, Belgium
| | - Stephen V Liu
- Michael J. Pishvaian and Stephen V. Liu, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Pratik S. Multani and Edna Chow-Maneval, Ignyta, San Diego, CA; and Christian Rolfo, Antwerp University Hospital and Center of Oncological Research, Antwerp University, Antwerp, Belgium
| | - Pratik S Multani
- Michael J. Pishvaian and Stephen V. Liu, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Pratik S. Multani and Edna Chow-Maneval, Ignyta, San Diego, CA; and Christian Rolfo, Antwerp University Hospital and Center of Oncological Research, Antwerp University, Antwerp, Belgium
| | - Edna Chow-Maneval
- Michael J. Pishvaian and Stephen V. Liu, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Pratik S. Multani and Edna Chow-Maneval, Ignyta, San Diego, CA; and Christian Rolfo, Antwerp University Hospital and Center of Oncological Research, Antwerp University, Antwerp, Belgium
| | - Christian Rolfo
- Michael J. Pishvaian and Stephen V. Liu, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Pratik S. Multani and Edna Chow-Maneval, Ignyta, San Diego, CA; and Christian Rolfo, Antwerp University Hospital and Center of Oncological Research, Antwerp University, Antwerp, Belgium
| |
Collapse
|
11
|
Levy MJF, Boulle F, Steinbusch HW, van den Hove DLA, Kenis G, Lanfumey L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology (Berl) 2018; 235:2195-2220. [PMID: 29961124 PMCID: PMC6061771 DOI: 10.1007/s00213-018-4950-4] [Citation(s) in RCA: 157] [Impact Index Per Article: 26.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Accepted: 06/18/2018] [Indexed: 02/06/2023]
Abstract
Depression is a major health problem with a high prevalence and a heavy socioeconomic burden in western societies. It is associated with atrophy and impaired functioning of cortico-limbic regions involved in mood and emotion regulation. It has been suggested that alterations in neurotrophins underlie impaired neuroplasticity, which may be causally related to the development and course of depression. Accordingly, mounting evidence suggests that antidepressant treatment may exert its beneficial effects by enhancing trophic signaling on neuronal and synaptic plasticity. However, current antidepressants still show a delayed onset of action, as well as lack of efficacy. Hence, a deeper understanding of the molecular and cellular mechanisms involved in the pathophysiology of depression, as well as in the action of antidepressants, might provide further insight to drive the development of novel fast-acting and more effective therapies. Here, we summarize the current literature on the involvement of neurotrophic factors in the pathophysiology and treatment of depression. Further, we advocate that future development of antidepressants should be based on the neurotrophin theory.
Collapse
Affiliation(s)
- Marion J F Levy
- Centre de Psychiatrie et Neurosciences (Inserm U894), Université Paris Descartes, 102-108 rue de la santé, 75014, Paris, France
- Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands
- EURON-European Graduate School of Neuroscience, Maastricht, The Netherlands
| | - Fabien Boulle
- Centre de Psychiatrie et Neurosciences (Inserm U894), Université Paris Descartes, 102-108 rue de la santé, 75014, Paris, France
- Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands
- EURON-European Graduate School of Neuroscience, Maastricht, The Netherlands
| | - Harry W Steinbusch
- Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands
- EURON-European Graduate School of Neuroscience, Maastricht, The Netherlands
| | - Daniël L A van den Hove
- Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands
- EURON-European Graduate School of Neuroscience, Maastricht, The Netherlands
- Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - Gunter Kenis
- Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands
- EURON-European Graduate School of Neuroscience, Maastricht, The Netherlands
| | - Laurence Lanfumey
- Centre de Psychiatrie et Neurosciences (Inserm U894), Université Paris Descartes, 102-108 rue de la santé, 75014, Paris, France.
- EURON-European Graduate School of Neuroscience, Maastricht, The Netherlands.
| |
Collapse
|
12
|
Merkouris S, Barde YA, Binley KE, Allen ND, Stepanov AV, Wu NC, Grande G, Lin CW, Li M, Nan X, Chacon-Fernandez P, DiStefano PS, Lindsay RM, Lerner RA, Xie J. Fully human agonist antibodies to TrkB using autocrine cell-based selection from a combinatorial antibody library. Proc Natl Acad Sci U S A 2018; 115:E7023-E7032. [PMID: 29987039 PMCID: PMC6065019 DOI: 10.1073/pnas.1806660115] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
The diverse physiological roles of the neurotrophin family have long prompted exploration of their potential as therapeutic agents for nerve injury and neurodegenerative diseases. To date, clinical trials of one family member, brain-derived neurotrophic factor (BDNF), have disappointingly failed to meet desired endpoints. Contributing to these failures is the fact that BDNF is pharmaceutically a nonideal biologic drug candidate. It is a highly charged, yet is a net hydrophobic molecule with a low molecular weight that confers a short t1/2 in man. To circumvent these shortcomings of BDNF as a drug candidate, we have employed a function-based cellular screening assay to select activating antibodies of the BDNF receptor TrkB from a combinatorial human short-chain variable fragment antibody library. We report here the successful selection of several potent TrkB agonist antibodies and detailed biochemical and physiological characterization of one such antibody, ZEB85. By using a human TrkB reporter cell line and BDNF-responsive GABAergic neurons derived from human ES cells, we demonstrate that ZEB85 is a full agonist of TrkB, comparable in potency to BDNF toward human neurons in activation of TrkB phosphorylation, canonical signal transduction, and mRNA transcriptional regulation.
Collapse
Affiliation(s)
- Spyros Merkouris
- School of Biosciences, Cardiff University, CF10 3AX Cardiff, United Kingdom
| | - Yves-Alain Barde
- School of Biosciences, Cardiff University, CF10 3AX Cardiff, United Kingdom
| | - Kate E Binley
- School of Biosciences, Cardiff University, CF10 3AX Cardiff, United Kingdom
| | - Nicholas D Allen
- School of Biosciences, Cardiff University, CF10 3AX Cardiff, United Kingdom
| | - Alexey V Stepanov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia
| | - Nicholas C Wu
- Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037
| | - Geramie Grande
- Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037
| | - Chih-Wei Lin
- Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037
| | - Meng Li
- School of Biosciences, Cardiff University, CF10 3AX Cardiff, United Kingdom
| | - Xinsheng Nan
- School of Biosciences, Cardiff University, CF10 3AX Cardiff, United Kingdom
| | | | | | | | - Richard A Lerner
- Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037;
| | - Jia Xie
- Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037;
| |
Collapse
|
13
|
Masjosthusmann S, Becker D, Petzuch B, Klose J, Siebert C, Deenen R, Barenys M, Baumann J, Dach K, Tigges J, Hübenthal U, Köhrer K, Fritsche E. A transcriptome comparison of time-matched developing human, mouse and rat neural progenitor cells reveals human uniqueness. Toxicol Appl Pharmacol 2018; 354:40-55. [PMID: 29753005 DOI: 10.1016/j.taap.2018.05.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 05/04/2018] [Accepted: 05/08/2018] [Indexed: 12/12/2022]
Abstract
It is widely accepted that human brain development has unique features that cannot be represented by rodents. Obvious reasons are the evolutionary distance and divergent physiology. This might lead to false predictions when rodents are used for safety or pharmacological efficacy studies. For a better translation of animal-based research to the human situation, human in vitro systems might be useful. In this study, we characterize developing neural progenitor cells from prenatal human and time-matched rat and mouse brains by analyzing the changes in their transcriptome profile during neural differentiation. Moreover, we identify hub molecules that regulate neurodevelopmental processes like migration and differentiation. Consequences of modulation of three of those hubs on these processes were studied in a species-specific context. We found that although the gene expression profiles of the three species largely differ qualitatively and quantitatively, they cluster in similar GO terms like cell migration, gliogenesis, neurogenesis or development of multicellular organism. Pharmacological modulation of the identified hub molecules triggered species-specific cellular responses. This study underlines the importance of understanding species differences on the molecular level and advocates the use of human based in vitro models for pharmacological and toxicological research.
Collapse
Affiliation(s)
- Stefan Masjosthusmann
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany.
| | - Daniel Becker
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany
| | - Barbara Petzuch
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany.
| | - Jördis Klose
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany.
| | - Clara Siebert
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany.
| | - Rene Deenen
- Biological and Medical Research Centre (BMFZ), Medical Faculty, Heinrich-Heine-University, Universitätsstraße 1, 40225 Duesseldorf, NRW, Germany.
| | - Marta Barenys
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany.
| | - Jenny Baumann
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany
| | - Katharina Dach
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany; Department of Molecular Biosciences, University of California-Davis School of Veterinary Medicine, Davis, CA 95616, United States.
| | - Julia Tigges
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany.
| | - Ulrike Hübenthal
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany.
| | - Karl Köhrer
- Biological and Medical Research Centre (BMFZ), Medical Faculty, Heinrich-Heine-University, Universitätsstraße 1, 40225 Duesseldorf, NRW, Germany.
| | - Ellen Fritsche
- IUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225 Duesseldorf, NRW, Germany; Medical Faculty, Heinrich-Heine-University, Universitätsstraße 1, 40225 Duesseldorf, NRW, Germany.
| |
Collapse
|
14
|
Siu JJ, Queen NJ, Liu X, Huang W, McMurphy T, Cao L. Molecular Therapy of Melanocortin-4-Receptor Obesity by an Autoregulatory BDNF Vector. Mol Ther Methods Clin Dev 2017; 7:83-95. [PMID: 29296625 PMCID: PMC5744069 DOI: 10.1016/j.omtm.2017.09.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2017] [Accepted: 09/26/2017] [Indexed: 12/27/2022]
Abstract
Mutations in the melanocortin-4-receptor (MC4R) comprise the most common monogenic form of severe early-onset obesity, and conventional treatments are either ineffective long-term or contraindicated. Immediately downstream of MC4R-in the pathway for regulating energy balance-is brain-derived neurotrophic factor (BDNF). Our previous studies show that adeno-associated virus (AAV)-mediated hypothalamic BDNF gene transfer alleviates obesity and diabetes in both diet-induced and genetic models. To facilitate clinical translation, we developed a built-in autoregulatory system to control therapeutic gene expression mimicking the body's natural feedback systems. This autoregulatory approach leads to a sustainable plateau of body weight after substantial weight loss is achieved. Here, we examined the efficacy and safety of autoregulatory BDNF gene therapy in Mc4r heterozygous mice, which best resemble MC4R obese patients. Mc4r heterozygous mice were treated with either autoregulatory BDNF vector or YFP control and monitored for 30 weeks. BDNF gene therapy prevented the development of obesity and metabolic syndromes characterized by decreasing body weight and adiposity, suppressing food intake, alleviating hyperleptinemia and hyperinsulinemia, improving glucose and insulin tolerance, and increasing energy expenditure, without adverse cardiovascular function or behavioral disturbances. These safety and efficacy data provide preclinical evidence that BDNF gene therapy is a compelling treatment option for MC4R-deficient obese patients.
Collapse
Affiliation(s)
- Jason J. Siu
- Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
- Neuroscience Graduate Program, The Ohio State University, Columbus, OH 43210, USA
- Medical Scientist Training Program, The Ohio State University, Columbus, OH 43210, USA
| | - Nicholas J. Queen
- Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
| | - Xianglan Liu
- Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
| | - Wei Huang
- Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
| | - Travis McMurphy
- Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
| | - Lei Cao
- Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
- Neuroscience Graduate Program, The Ohio State University, Columbus, OH 43210, USA
- Medical Scientist Training Program, The Ohio State University, Columbus, OH 43210, USA
- The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
| |
Collapse
|
15
|
Bailey JJ, Schirrmacher R, Farrell K, Bernard-Gauthier V. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II. Expert Opin Ther Pat 2017; 27:831-849. [PMID: 28270021 DOI: 10.1080/13543776.2017.1297797] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
INTRODUCTION TrkA/B/C receptor activation supports growth, survival, and differentiation of discrete neuronal populations during development, adult life, and ageing but also plays numerous roles in human disease onset and progression. Trk-specific inhibitors have therapeutic applications in cancer and pain and thus constitute a growing area of interest in oncology and neurology. There has been substantial growth in the number of structural classes of Trk inhibitors and the number of industrial entrants to the Trk inhibitor field over the past six years. Areas covered: In Part II of this two-part review, the discussion of recent patent literature covering Trk family inhibitors is continued from Part I and clinical research with Trk inhibitors is considered. Expert opinion: Trk has been molecularly targeted for over a decade resulting in the progressive evolution of structurally diversified Trk inhibitors arising from scaffold hopping and HTS efforts. Correspondingly, there have been a growing number of clinical investigations utilizing Trk inhibitors in recent years, with a particular focus on the treatment of NTRK-fusion positive cancers and chronic pain. The observed potential of Trk inhibitors to cause adverse CNS side effects however suggests the need for a more rigorous consideration of BBB permeation capabilities during drug development.
Collapse
Affiliation(s)
- Justin J Bailey
- a Faculty of Medicine & Dentistry, Department of Oncology , University of Alberta , Edmonton , Canada
| | - Ralf Schirrmacher
- a Faculty of Medicine & Dentistry, Department of Oncology , University of Alberta , Edmonton , Canada
| | - Kristen Farrell
- a Faculty of Medicine & Dentistry, Department of Oncology , University of Alberta , Edmonton , Canada
| | - Vadim Bernard-Gauthier
- a Faculty of Medicine & Dentistry, Department of Oncology , University of Alberta , Edmonton , Canada
| |
Collapse
|
16
|
Abstract
The global rise in the prevalence of obesity and associated co-morbidities such as type 2 diabetes, cardiovascular disease, and cancer represents a major public health concern. The biological response to increased consumption of palatable foods or a reduction in energy expenditure is highly variable between individuals. A more detailed mechanistic understanding of the molecular, physiological, and behavioral pathways involved in the development of obesity in susceptible individuals is critical for identifying effective mechanism-based preventative and therapeutic interventions.
Collapse
Affiliation(s)
- Agatha A van der Klaauw
- University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
| | - I Sadaf Farooqi
- University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
| |
Collapse
|
17
|
Fritsche E, Alm H, Baumann J, Geerts L, Håkansson H, Masjosthusmann S, Witters H. Literature review on in vitro and alternative Developmental Neurotoxicity (DNT) testing methods. ACTA ACUST UNITED AC 2015. [DOI: 10.2903/sp.efsa.2015.en-778] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Ellen Fritsche
- Leibniz Research Institute for Environmental Medicine (IUF), Group of Sphere Models and Risk Assessment, Auf'm Hennekamp 50, 40225 Düsseldorf, Germany
| | - Henrik Alm
- Leibniz Research Institute for Environmental Medicine (IUF), Group of Sphere Models and Risk Assessment, Auf'm Hennekamp 50, 40225 Düsseldorf, Germany
| | - Jenny Baumann
- Leibniz Research Institute for Environmental Medicine (IUF), Group of Sphere Models and Risk Assessment, Auf'm Hennekamp 50, 40225 Düsseldorf, Germany
| | - Lieve Geerts
- Flemish Institute for Technological Research (VITO), Environmental Risk & Health, Boeretang 200, B‐2400 Mol, Belgium
| | - Helen Håkansson
- Karolinska Institute (KI), Institute of Environmental Medicine (IMM), Unit of Environmental Health Risk Assessment, SE‐171 77 Stockholm, Sweden
| | - Stefan Masjosthusmann
- Leibniz Research Institute for Environmental Medicine (IUF), Group of Sphere Models and Risk Assessment, Auf'm Hennekamp 50, 40225 Düsseldorf, Germany
| | - Hilda Witters
- Flemish Institute for Technological Research (VITO), Environmental Risk & Health, Boeretang 200, B‐2400 Mol, Belgium
| |
Collapse
|
18
|
Mrzljak L, Munoz-Sanjuan I. Therapeutic Strategies for Huntington's Disease. Curr Top Behav Neurosci 2013; 22:161-201. [PMID: 24277342 DOI: 10.1007/7854_2013_250] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Huntington's disease (HD) is a devastating autosomal dominant neurodegenerative disease, caused by expansion of the CAG repeat in the huntingtin (HTT) gene and characterized pathologically by the loss of pyramidal neurons in several cortical areas, of striatal medium spiny neurons, and of hypothalamic neurons. Clinically, a distinguishing feature of the disease is uncontrolled involuntary movements (chorea, dyskensias) accompanied by progressive cognitive, motor, and psychiatric impairment. This review focuses on the current state of therapeutic development for the treatment of HD, including the preclinical and clinical development of small molecules and molecular therapies.
Collapse
|